Igamad

Human Anti-D Immunoglobulin, the active ingredient in Igamad, is an immunoglobulin presented as an injectable solution for intramuscular use. It provides passive immunity to Rh‑negative pregnant women, preventing maternal sensitization to the D antigen and reducing the risk of hemolytic disease of the fetus and newborn. GNH USA supplies Igamad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, with established cold‑chain logistics and regulatory support. Our network ensures timely delivery and compliance with local import requirements.

Igamad, an anti‑D immune globulin, is used in the Rh‑D alloimmunization pathway to prevent maternal sensitization.

Rh‑negative pregnancy: prevents maternal immune sensitization to the D antigen, reducing risk of hemolytic disease of the fetus and newborn. Rh incompatibility in subsequent pregnancies: maintains protection after initial prophylaxis, lowering the chance of alloimmunization in later gestations. Post‑miscarriage or invasive obstetric procedures: provides passive immunity to avoid sensitization following events that may expose fetal red cells to the maternal circulation.

Igamad may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Pain or tenderness at the injection site - Low‑grade fever or chills - Headache - Nausea or mild gastrointestinal upset - Transient rash or urticaria - Fatigue or malaise

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Hemolysis or severe anemia - Thrombocytopenia or bleeding disorders - Serum sickness-like reaction - Severe hypotension or shock - Disseminated intravascular coagulation (DIC)

When using Igamad, several safety measures should be observed.

Screening: confirm Rh‑negative status before administration. Timing: give within 72 hours of a potentially sensitizing event. Allergy: avoid in patients with known IgA deficiency or severe prior reactions to immunoglobulins. Pregnancy: use only under obstetric supervision. Concomitant therapy: monitor when given with other blood products. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igamad can interact with other agents; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Live vaccines: may interfere with vaccine efficacy; avoid concurrent administration. - Potent immunosuppressants: may reduce the prophylactic effect of anti‑D immunoglobulin.

Moderate Interactions (Monitor Closely): - Intravenous immunoglobulin (IVIG) products: increased risk of hyperviscosity. - Anticoagulants: monitor for excessive bruising or bleeding at injection sites. - Monoclonal antibodies targeting Fc receptors: may alter clearance of Igamad.